This review article provides an overview of the main adverse events, risk assessment and risk mitigation strategies, early diagnosis, medical and complementary strategies for prevention and management, and long‐term follow‐up strategies for patients at risk of experiencing cancer therapy‐related cardiotoxicities

This position statement reviews the use of echocardiography, cardiac magnetic resonance, nuclear cardiac imaging, and computed tomography in the management of cancer patients based on current evidence for the value of modern cardiovascular imaging in the cardio‐oncology field, and discusses future directions and ongoing cardiovascular imaging research.

This position statement presents evidence‐based risk stratification tools for oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities.

The most recent update to the NCCN Survivorship guidelines has added a new algorithm for cardiovascular disease risk assessment among cancer survivors, which includes the ABCDEs to Promote Cardiovascular Wellness (SCVD-1 and SCVD-1).

This review article explores the links between cancer, cancer treatment, and cardiovascular risk, including mechanisms associated with cardiotoxicity, screening and surveillance for patients undergoing cancer treatment, and effective preventative and management strategies used to reduce the incidence of cardiotoxicities in patients receiving chemotherapeutics or radiation.

This curated resource from the American College of Cardiology offers links to cardio-oncology news and JACC journal articles, education and meeting opportunities, and tools and practice support for clinicians.

Through this webpage, the International Cardio-Oncology Society provides myriad resources to help both clinicians and patients stay aware and informed about the latest in cardio-oncology.

Discover the myocardial biology behind cardiotoxicity associated with kinase inhibitor therapies through this presentation from the 2019 FDA conference, “Cardiomyocytes for Mechanistic Cardiovascular Safety Liabilities."

Check out the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group’s recommendations to standardize management of toxicities associated with immune checkpoint inhibitor therapy.

This patient resource provides helpful information on adverse events associated with immune checkpoint inhibitor therapy, including myocarditis, pericarditis, arrythmias, impaired ventricular function, and conduction abnormalities.

This detailed resource from the Australian Cancer Institute NSW provides information on prevention, assessment, and management of cardiac toxicity associated with HER2-targeted therapies, and more.

Take a deep dive into the clinical mitigation and management of osimertinib-induced heart failure in a 67-year old patient with metastatic EGFR-mutant lung adenocarcinoma and a history of hypertension, hypothyroidism, and pulmonary embolism in this Clinical Case Challenge.

This patient resource provides helpful information on adverse events associated with CAR T-cell therapy, including cytokine release syndrome–related atrial fibrillation, ventricular tachycardia, and decrease heart performance.

This Viewpoint article highlights the importance of reconsidering certain clinical visits, including imaging tests, for patients with cancer and/or cardiovascular disease during the ongoing COVID-19 pandemic. The authors also provide general guidance, based on available evidence, regarding the role of routine cardiac surveillance as the novel coronavirus continues to be a threat.

Developed by an American Society of Clinical Oncology expert panel and based on a systematic review of literature, these guidelines equip health care providers to discuss potential cardiac dysfunction with patients at high risk and initiate appropriate prevention and screening measures prior to beginning therapy.

This review published in Current Treatment Options in Cardiovascular Medicine details cardiotoxicities associated with immune checkpoint inhibitor therapy, focusing on myocarditis.

Learn from the multidisciplinary team of cardio-oncology specialists at Memorial Sloan Kettering Cancer Center about how to balance the anticipated benefits of breast cancer therapy with cardiovascular risk and helpful strategies to prevent cardiotoxicity and improve outcomes and long-term quality of life for breast cancer survivors.

Walk through the case of a 61-year-old patient with chronic myeloid leukemia and no cardiovascular history experiencing cardiac side effects associated with nilotinib treatment, including management and clinical perspective in this Clinical Case Challenge.

Read about and listen to nationally recognized expert Elizabeth Shpall, MD, of the University of Texas MD Anderson Cancer Center, as she details best practices for managing cytokine release syndrome among patients receiving CAR T-cell therapy.

The ESMO Clinical Practice Guidelines review the main immune-related adverse events associated with immunotherapy, including myocarditis, and include recommendations for their management.

This comprehensive review from Breast Cancer Research and Treatment analyses clinical trials of trastuzumab, lapatinib, pertuzumab, T-DM1, and neratinib in breast cancer. The authors discuss incidence and mechanisms for cardiotoxicity of HER2-targeted therapies, in addition to summarizing practices in management of cardiotoxicity for routine patient care.

These recommendations offer a critical summary of adverse events that emerge during CML treatment, as well as guidelines for management and prevention, in an effort to improve TKI compliance and improve outcomes.

Check out this primer in cardio-oncology for a summary of the current understanding of cardiovascular toxicities associated with CD19-specific CAR T-cell therapies, proposed cardiac surveillance protocol for patients receiving the therapy, and discussion of what’s on the horizon for cardio-oncology research in this area.

Stay up to date about emerging research on the cardiotoxicities seen with many types of cancer therapy. Learn about why these cardiac effects occur, and how to best monitor for and manage them in your patients. 

Learn about the development and implementation of a cardio-oncology program in a suburban community cardiology practice, created to provide service in this area to breast cancer patients at risk for cardiotoxicity, including the use of the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework to guide the project and enhance the translation of research into practice through planning and execution.

Take a deep dive into the clinical mitigation and management of osimertinib-induced heart failure in a 67-year old patient with metastatic EGFR-mutant lung adenocarcinoma and a history of hypertension, hypothyroidism, and pulmonary embolism in this Clinical Case Challenge.

This review explores current data on risk factors, diagnoses, and treatment options that impact cardio-oncologic patients with COVID-19, in addition to offering strategies for the treatment and management of this population.

The patient section of the Canadian Cardiac Oncology Network’s site offers patients access to information about cardiac oncology, including educational resources, clinical trials, and research articles, in addition to a frequently asked questions list and Canadian-specific clinic search.

This resource provides a click-through and searchable listing of cancer drugs, their drug class and cancer indications, and their associated cardio-toxicities, to help clinicians stay informed when treating their patients.

Learn about the etiology, mechanism, and clinical management of cytokine release syndrome—a side effect associated with novel immunotherapeutics such as CAR T-cell and bispecific T-cell engager therapies—on the cardiovascular and other organ systems, as well as grading and treatment modalities. The aim is to maximize the benefit of CAR T-cell therapy while mitigating the risk of cardiac complications.

This JADPRO article highlights current and emerging data on HER2-directed therapies and outlines strategies for managing adverse events—including cardiotoxicity.

Find guidance on managing various cardiotoxicities associated with HER2-targeted therapies approved for the treatment for breast cancer.

Explore the existing literature relating to chemotherapy- and radiotherapy-induced cardiotoxicity in this review. Also learn about the imaging modalities used to identify cardiotoxicity, as well as prevention and management therapies.

This expert analysis from the American College of Cardiology takes a deep dive into the risk of atrial fibrillation associated with the Bruton kinase inhibitor ibrutinib and a proposed algorithm for management of this toxicity.

Currently in development, the SITC Cancer Immunotherapy Guidelines (CIGs) will provide consensus statements developed by experts in the treatment of specific types of cancer, each with key indicators to help practicing oncologists determine when and how to best use immunotherapy to treat their patients, including toxicity management.

Get up to speed on CAR T-cell therapy: how it works, which patients are candidates, what side effects to be on alert for, and what your institution needs to do to prepare to offer this revolutionary therapy.

Educate yourself and your team members about the growing list of BTK inhibitors, where they fit in the treatment landscape, and how to successfully manage patients receiving these agents. 

Find guidance on managing various cardiotoxicities associated with approved immunotherapies approved for the treatment of cancer.

Recognize the signs/symptoms and understand the risk factors that may be associated with the development of CAR T-cell therapy–associated cytokine release syndrome (CRS), including its cardiovascular impact, as well as the incidence, severity, and timing of CRS with different CAR T-cell products to enable earlier recognition and treatment, and therefore improvement of outcomes in patients receiving this novel therapy.

Find guidance on managing various cardiotoxicities associated with kinase inhibitors approved for the treatment for B-cell lymphomas.

Find guidance on managing various cardiotoxicities associated with kinase inhibitors approved for the treatment for CLL/SLL.

Find guidance on managing various cardiotoxicities associated with kinase inhibitors approved for the treatment for CML

This patient-focused webpage provides information on the different types of HER2-targeted therapies and associated cardiovascular concerns.

Review this article geared to clinicians for up-to-date information on the cardiotoxicities associated with trastuzumab and other HER2-targeted therapies

Check out ASCO’s practice guideline recommendations on managing immune-related adverse events—including cardiotoxicities—among patients how receive immune checkpoint inhibitor treatment.

Learn about emerging concerns in the diagnosis and management of immune checkpoint inhibitor–associated cardiotoxicity in this Expert Analysis from the American College of Cardiology.